News

Caixa Capital Risc acquires a stake in AlgaEnergy, leader in innovation in the microalgae sector

• CriteriaCaixa’s venture capital management company and the CDTI fund Innvierte Economía Sostenible will have a minority stake in the company.
• AlgaEnergy develops and markets biological agricultural inputs that increase the productivity and quality of crops in a sustainable and profitable way, as well as cosmetic and nutrition products, always with a focus on sustainability and functionality for the user.
• This transaction consolidates the growth strategy of the industrial area of Caixa Capital Risc, which channels its new investments through Criteria Industrial Ventures.
• Caixa Capital Risc manages a volume of more than €230 million in over 120 innovative companies in Spain and Portugal.

| Read more |

Caixa Capital Risc strengthens its commitment to the cybersecurity business by acquiring a stake in start-up company Build38 and searches for success cases of emerging companies

• Caixa Capital Risc co-leads, together with the German fund eCapital, an investment of 3 million euros in the cybersecurity startup, whose solution represents a new generation of services and technologies that protect mobile apps.
• Build38 is based in Munich and its development team is located in Barcelona. It also has an office in Singapore.

| Read more |

Medlumics raises €14M in a Series E financing co-led by Asabys Partners, VI Partners and CDTI Innvierte, together with existing investors Andera Partners, Caixa Capital Risc and Innogest

• Medlumics develops a unique real-time, photonically guided radiofrequency (RF) irrigated ablation catheter to improve the treatment of Atrial Fibrillation
• The proceeds from the Series E financing will be used to complete the preclinical development and obtain first in human data
•Medlumics strong investor syndicate includes Asabys Partners, VI Partners, Andera Partners, Caixa Capital Risc, Innogest Capital and CDTI Innvierte

| Read more |

Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau

• Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition
• Minoryx will receive an upfront and milestone payments of up to $78 million, as well as double digit royalties on annual net sales

| Read more |

Caixa Capital Risc takes the award for the best Venture Capital deal of the year for the sale of PlayGiga to Facebook

• Caixa Capital Risc invested nearly 14 million euros in 2019 in 40 startups and made 20 divestments to boost its investment portfolio.
• The CriteriaCaixa venture capital management company currently manages a portfolio of 228 million euros, with 123 companies.

| Read more |